title: Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy.
abstract: BACKGROUND
  We evaluated the predictive significance of 14 reported markers using immunohistochemical study in nasopharyngeal carcinoma.
  
  
  METHODS
  Immunohistochemical stainings were done in 38 patients for Met, cyclooxygenase-2 (COX-2), nm23-H1, epidermal growth factor receptor (EGFR), p63, early growth response factor 1 (Egr1), chromosome segregation 1-like (CSE1L), cathepsin-D (aspartyl protease), C-erbB2, p53, signal transducers and activators of transcription (STAT3/STAT5), CD138 (Syndecan-1), and LIN28 with the usual methods.
  
  
  RESULTS
  The median follow-up time was 30 months (11-83 months). High Met and CD138 expression were statistically significant negative prognostic factors on survival. The expression of Egr1 had a positive prognostic effect on survival. The combined score of these 3 markers, Met plus CD138 minus Egr1, was a strong prognostic factor. The median survival curve was distinctly separated in accord with this combined score. No prognostic value was revealed in COX-2, nm23-H1, EGFR, p63, CSE1L, cathepsin-D, C-erbB2, p53, STAT3, STAT5, and LIN28.
  
  
  CONCLUSIONS
  The combined score of these markers could be used to stratify biomolecular risk groups.
authors.affiliation: Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Yeon-Joo
authors.initials: YJ
authors.lastname: Kim
authors.forename: Heounjeong
authors.initials: H
authors.lastname: Go
authors.forename: Hong-Gyun
authors.initials: HG
authors.lastname: Wu
authors.forename: Yoon Kyung
authors.initials: YK
authors.lastname: Jeon
authors.forename: Suk Won
authors.initials: SW
authors.lastname: Park
authors.forename: Seung Hee
authors.initials: SH
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002277:Carcinoma / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D002402:Cathepsin D / Q000378:metabolism; D029563:Cellular Apoptosis Susceptibility Protein / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D051546:Cyclooxygenase 2 / Q000378:metabolism; D018572:Disease-Free Survival; D051766:Early Growth Response Protein 1 / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D054778:NM23 Nucleoside Diphosphate Kinases / Q000378:metabolism; D009303:Nasopharyngeal Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000628:therapy; D011379:Prognosis; D019859:Proto-Oncogene Proteins c-met / Q000378:metabolism; D016601:RNA-Binding Proteins / Q000378:metabolism; D050397:Radiotherapy, Intensity-Modulated; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D050796:STAT3 Transcription Factor / Q000378:metabolism; D050799:STAT5 Transcription Factor / Q000378:metabolism; D053668:Syndecan-1 / Q000378:metabolism; D014157:Transcription Factors / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D025521:Tumor Suppressor Proteins / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D002402:Cathepsin D; D029563:Cellular Apoptosis Susceptibility Protein; D051546:Cyclooxygenase 2; D051766:Early Growth Response Protein 1; D066246:ErbB Receptors; D054778:NM23 Nucleoside Diphosphate Kinases; D019859:Proto-Oncogene Proteins c-met; D016601:RNA-Binding Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D050796:STAT3 Transcription Factor; D050799:STAT5 Transcription Factor; D053668:Syndecan-1; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; C000715187:Lin28A protein, human; C115051:TP63 protein, human; C491743:MET protein, human; C517938:NME1 protein, human